找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Nachhaltigkeit erm?glichen; Vom Buzzword zur gel Sabrina Krauss,Philipp Plugmann Book 2024 Der/die Herausgeber bzw. der/die Autor(en), exkl

[復(fù)制鏈接]
樓主: OBESE
31#
發(fā)表于 2025-3-27 00:08:59 | 只看該作者
32#
發(fā)表于 2025-3-27 03:48:58 | 只看該作者
33#
發(fā)表于 2025-3-27 08:00:56 | 只看該作者
34#
發(fā)表于 2025-3-27 12:21:05 | 只看該作者
35#
發(fā)表于 2025-3-27 17:07:20 | 只看該作者
36#
發(fā)表于 2025-3-27 20:56:02 | 只看該作者
Sabrina Krausss can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical com
37#
發(fā)表于 2025-3-27 23:07:36 | 只看該作者
Julia Plugmann,Philipp Plugmanns can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical com
38#
發(fā)表于 2025-3-28 04:26:46 | 只看該作者
Arno Lammertss can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical com
39#
發(fā)表于 2025-3-28 06:33:28 | 只看該作者
40#
發(fā)表于 2025-3-28 12:20:05 | 只看該作者
Andreas Kirstas well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall s
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 19:12
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
色达县| 卢氏县| 治多县| 株洲市| 东台市| 腾冲县| 宁阳县| 中西区| 新邵县| 高平市| 松江区| 商丘市| 武清区| 佛山市| 壶关县| 垦利县| 南皮县| 陆丰市| 恭城| 胶州市| 木里| 绥芬河市| 唐山市| 溆浦县| 延川县| 南皮县| 依安县| 五华县| 芒康县| 嘉义市| 潜山县| 大新县| 凯里市| 金川县| 韩城市| 改则县| 印江| 阳泉市| 昆山市| 舒兰市| 云梦县|